2026 Q2 - tulosraportti
34 päivää sitten
‧51 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 58 | - | - | ||
| 6 306 | - | - | ||
| 1 000 | - | - | ||
| 1 505 | - | - | ||
| 452 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 t sitten · Muokattuhttps://meetingonthemesa.com/company-presentation/circio/ On the official Mesa page, it states verbatim that: “Circio is the global leader in vector-based circRNA expression systems” and further: “with no known competitors with comparable versatility and performance.” Circio itself claims to be the global leader within vector-based circRNA expression systems. At the same time, they state that they are not aware of any competitors with a corresponding combination of versatility and performance. This is published on the official presentation page of the Cell & Gene Meeting on the Mesa, and Circio is listed as the company being presented. It is interesting that the organizer has chosen to present precisely this formulation to an international pharma/biotech audience.Large international arena: 1,500+ participants and 5,000+ partner/BD meetings. Circio gets its own presentation for a heavy pharma/biotech audience. Strong positioning: Circio is referred to as "global leader" within vector-based circRNA expression systems. Extra interesting: The company claims no known competitors match the same breadth and performance. Timing: exciting towards upcoming collaborations, in-vivo CAR-T and disease model data.
·4 t sitten · MuokattuVictor Levitsky, Chief Scientific Officer 6 Oct. | 09:15 | FLW Ballroom F Huddinge (Stockholm), Sweden(OSE: CRNA) Circio is a publicly listed biotechnology company that has established a unique and proprietary intracellular circular RNA (circRNA) expression system, circVec, which significantly improves the potency and durability of gene expression, which is critical for gene therapies. circVec is designed for efficient biogenesis of circRNA from DNA and viral vectors, with primary application in AAV gene therapy and in vivo T-cell therapy. Following AAV delivery, circVec has demonstrated up to 50 times improved gene expression compared to conventional mRNA-based AAV gene therapy in several organs and tissues such as heart and eye, and six months of expression durability for LNP-delivered payload in spleen. Circio is the global leader in vector-based circRNA expression systems with no known competitors of comparable versatility and performance. circVec's R&D activities are carried out in the wholly owned subsidiary Circio AB, located in the Novum Labs building at the Karolinska Institute Campus in Huddinge (Stockholm), Sweden. www.circio.com Cell & Gene Meeting on the Mesa is the sector's premier annual conference bringing together top executives and industry decision-makers to advance groundbreaking cure research. This meeting tackles the commercialization hurdles facing the cell and gene therapy sector today, covering a wide range of topics from clinical trial design to alternative payment models to scaling and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering opportunities, exclusive networking opportunities, and over 100 dedicated presentations by the industry's leading publicly traded and privately held companies. With over 1,500 attendees – over 30% of whom are senior executives – this conference enables vital partnerships through more than 5,000 one-on-one meetings while highlighting significant clinical and commercial progress in the field. Dates and Location October 5–7, 2026 Arizona Biltmore Phoenix, AZ Program Organizer
·5 t sitten · MuokattuThen today's meeting is finished Exciting times ahead of us🥳https://youtu.be/_l3E6f5jgoM?feature=shared Surely more than me who need to hear/see this again!
·6 t sittenIt is wonderful to finally close above 11 kroner today, and that by a good margin. Now we have been down and tested the 10s twice after the latest share issue, with similar liquidity and trading pattern as when we were at the 7s this summer. That the trading practically slowed down in the lower and middle 10s just shows how much the share price has developed and strengthened since summer. There are probably many here on the forum who feel that it is only going downwards/sideways for Circio, but if you zoom out the chart you will see that the peaks and troughs are constantly being pushed upwards, which makes good sense because Circio as a company is developing in an extremely positive direction. I will be surprised if we are pushed below the 11s again in the near future. Now I believe the issue price will be next stop and hopefully we break the 12s without too much resistance.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
34 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 t sitten · Muokattuhttps://meetingonthemesa.com/company-presentation/circio/ On the official Mesa page, it states verbatim that: “Circio is the global leader in vector-based circRNA expression systems” and further: “with no known competitors with comparable versatility and performance.” Circio itself claims to be the global leader within vector-based circRNA expression systems. At the same time, they state that they are not aware of any competitors with a corresponding combination of versatility and performance. This is published on the official presentation page of the Cell & Gene Meeting on the Mesa, and Circio is listed as the company being presented. It is interesting that the organizer has chosen to present precisely this formulation to an international pharma/biotech audience.Large international arena: 1,500+ participants and 5,000+ partner/BD meetings. Circio gets its own presentation for a heavy pharma/biotech audience. Strong positioning: Circio is referred to as "global leader" within vector-based circRNA expression systems. Extra interesting: The company claims no known competitors match the same breadth and performance. Timing: exciting towards upcoming collaborations, in-vivo CAR-T and disease model data.
- ·4 t sitten · MuokattuVictor Levitsky, Chief Scientific Officer 6 Oct. | 09:15 | FLW Ballroom F Huddinge (Stockholm), Sweden(OSE: CRNA) Circio is a publicly listed biotechnology company that has established a unique and proprietary intracellular circular RNA (circRNA) expression system, circVec, which significantly improves the potency and durability of gene expression, which is critical for gene therapies. circVec is designed for efficient biogenesis of circRNA from DNA and viral vectors, with primary application in AAV gene therapy and in vivo T-cell therapy. Following AAV delivery, circVec has demonstrated up to 50 times improved gene expression compared to conventional mRNA-based AAV gene therapy in several organs and tissues such as heart and eye, and six months of expression durability for LNP-delivered payload in spleen. Circio is the global leader in vector-based circRNA expression systems with no known competitors of comparable versatility and performance. circVec's R&D activities are carried out in the wholly owned subsidiary Circio AB, located in the Novum Labs building at the Karolinska Institute Campus in Huddinge (Stockholm), Sweden. www.circio.com Cell & Gene Meeting on the Mesa is the sector's premier annual conference bringing together top executives and industry decision-makers to advance groundbreaking cure research. This meeting tackles the commercialization hurdles facing the cell and gene therapy sector today, covering a wide range of topics from clinical trial design to alternative payment models to scaling and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering opportunities, exclusive networking opportunities, and over 100 dedicated presentations by the industry's leading publicly traded and privately held companies. With over 1,500 attendees – over 30% of whom are senior executives – this conference enables vital partnerships through more than 5,000 one-on-one meetings while highlighting significant clinical and commercial progress in the field. Dates and Location October 5–7, 2026 Arizona Biltmore Phoenix, AZ Program Organizer
- ·5 t sitten · MuokattuThen today's meeting is finished Exciting times ahead of us🥳https://youtu.be/_l3E6f5jgoM?feature=shared Surely more than me who need to hear/see this again!
- ·6 t sittenIt is wonderful to finally close above 11 kroner today, and that by a good margin. Now we have been down and tested the 10s twice after the latest share issue, with similar liquidity and trading pattern as when we were at the 7s this summer. That the trading practically slowed down in the lower and middle 10s just shows how much the share price has developed and strengthened since summer. There are probably many here on the forum who feel that it is only going downwards/sideways for Circio, but if you zoom out the chart you will see that the peaks and troughs are constantly being pushed upwards, which makes good sense because Circio as a company is developing in an extremely positive direction. I will be surprised if we are pushed below the 11s again in the near future. Now I believe the issue price will be next stop and hopefully we break the 12s without too much resistance.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 58 | - | - | ||
| 6 306 | - | - | ||
| 1 000 | - | - | ||
| 1 505 | - | - | ||
| 452 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
34 päivää sitten
‧51 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
Sijoittajakalenteri ei ole saatavilla | |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 1.9. | ||
2025 Q4 - tulosraportti 15.4. | ||
2025 Q2 - tulosraportti 28.8.2025 | ||
2024 Q4 - tulosraportti 10.4.2025 | ||
2024 Q2 - tulosraportti 29.8.2024 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·3 t sitten · Muokattuhttps://meetingonthemesa.com/company-presentation/circio/ On the official Mesa page, it states verbatim that: “Circio is the global leader in vector-based circRNA expression systems” and further: “with no known competitors with comparable versatility and performance.” Circio itself claims to be the global leader within vector-based circRNA expression systems. At the same time, they state that they are not aware of any competitors with a corresponding combination of versatility and performance. This is published on the official presentation page of the Cell & Gene Meeting on the Mesa, and Circio is listed as the company being presented. It is interesting that the organizer has chosen to present precisely this formulation to an international pharma/biotech audience.Large international arena: 1,500+ participants and 5,000+ partner/BD meetings. Circio gets its own presentation for a heavy pharma/biotech audience. Strong positioning: Circio is referred to as "global leader" within vector-based circRNA expression systems. Extra interesting: The company claims no known competitors match the same breadth and performance. Timing: exciting towards upcoming collaborations, in-vivo CAR-T and disease model data.
- ·4 t sitten · MuokattuVictor Levitsky, Chief Scientific Officer 6 Oct. | 09:15 | FLW Ballroom F Huddinge (Stockholm), Sweden(OSE: CRNA) Circio is a publicly listed biotechnology company that has established a unique and proprietary intracellular circular RNA (circRNA) expression system, circVec, which significantly improves the potency and durability of gene expression, which is critical for gene therapies. circVec is designed for efficient biogenesis of circRNA from DNA and viral vectors, with primary application in AAV gene therapy and in vivo T-cell therapy. Following AAV delivery, circVec has demonstrated up to 50 times improved gene expression compared to conventional mRNA-based AAV gene therapy in several organs and tissues such as heart and eye, and six months of expression durability for LNP-delivered payload in spleen. Circio is the global leader in vector-based circRNA expression systems with no known competitors of comparable versatility and performance. circVec's R&D activities are carried out in the wholly owned subsidiary Circio AB, located in the Novum Labs building at the Karolinska Institute Campus in Huddinge (Stockholm), Sweden. www.circio.com Cell & Gene Meeting on the Mesa is the sector's premier annual conference bringing together top executives and industry decision-makers to advance groundbreaking cure research. This meeting tackles the commercialization hurdles facing the cell and gene therapy sector today, covering a wide range of topics from clinical trial design to alternative payment models to scaling and supply chain platforms for advanced therapies. The program features expert-led panels, extensive partnering opportunities, exclusive networking opportunities, and over 100 dedicated presentations by the industry's leading publicly traded and privately held companies. With over 1,500 attendees – over 30% of whom are senior executives – this conference enables vital partnerships through more than 5,000 one-on-one meetings while highlighting significant clinical and commercial progress in the field. Dates and Location October 5–7, 2026 Arizona Biltmore Phoenix, AZ Program Organizer
- ·5 t sitten · MuokattuThen today's meeting is finished Exciting times ahead of us🥳https://youtu.be/_l3E6f5jgoM?feature=shared Surely more than me who need to hear/see this again!
- ·6 t sittenIt is wonderful to finally close above 11 kroner today, and that by a good margin. Now we have been down and tested the 10s twice after the latest share issue, with similar liquidity and trading pattern as when we were at the 7s this summer. That the trading practically slowed down in the lower and middle 10s just shows how much the share price has developed and strengthened since summer. There are probably many here on the forum who feel that it is only going downwards/sideways for Circio, but if you zoom out the chart you will see that the peaks and troughs are constantly being pushed upwards, which makes good sense because Circio as a company is developing in an extremely positive direction. I will be surprised if we are pushed below the 11s again in the near future. Now I believe the issue price will be next stop and hopefully we break the 12s without too much resistance.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 58 | - | - | ||
| 6 306 | - | - | ||
| 1 000 | - | - | ||
| 1 505 | - | - | ||
| 452 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt